[{"AccountsPayableCurrent_0_Q2_USD":8642000.0,"OtherNoncashIncomeExpense_2_Q2_USD":0.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":1251000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":0.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":0.0,"OtherAssetsNoncurrent_0_Q2_USD":12742000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":3525000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":8835000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":8159000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1968000.0,"OperatingIncomeLoss_2_Q2_USD":-75668000.0,"OperatingIncomeLoss_1_Q2_USD":-18346000.0,"NumberOfReportableSegments_2_Q2_segment":1.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"NetIncomeLoss_2_Q2_USD":-83251000.0,"NetIncomeLoss_1_Q2_USD":-21591000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-76578000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-87774000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":15135000.0,"MarketableSecuritiesCurrent_0_Q2_USD":97848000.0,"LiabilitiesCurrent_0_Q2_USD":268336000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":679540000.0,"Liabilities_0_Q2_USD":1062467000.0,"InvestmentIncomeInterest_2_Q2_USD":178000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":94448000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":361000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":18112000.0,"ProceedsFromCollaborators_2_Q2_USD":0.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":92019987.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":92355150.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":11045000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":1255578.0,"StockholdersEquity_0_Q2_USD":-382927000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q2_shares":7747596.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":7747596.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1057349.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_Q2_shares":347506.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":4942410.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_2_Q2_USD":1300000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1_Q2_USD":1300000.0,"InvestmentIncomeInterest_1_Q2_USD":100000.0,"ShareBasedCompensation_2_Q2_USD":23125000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":58781000.0,"Revenues_2_Q2_USD":118965000.0,"Revenues_1_Q2_USD":77902000.0,"RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2_Q2_USD":54681000.0,"RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1_Q2_USD":25172000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1129399000.0,"RestrictedCash_0_Q2_USD":10100000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":57160000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":26280000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3297000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":15135000.0,"ProceedsFromRelatedPartyDebt_2_Q2_USD":0.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":119993000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":92355150.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":1960000.0,"InventoryNet_0_Q2_USD":6141000.0,"DeferredRevenueCurrent_0_Q2_USD":100564000.0,"DeferredCompensationShareBasedArrangementsLiabilityCurrent_0_Q2_USD":5769000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-83251000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-21591000.0,"CommonStockValue_0_Q2_USD":2000.0,"CommonStockSharesOutstanding_0_Q2_shares":93077789.0,"CommonStockSharesIssued_0_Q2_shares":93077789.0,"CommonStockSharesAuthorized_0_Q2_shares":564111242.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0,"CommitmentsAndContingencies_0_Q2_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-149217000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":528263000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":616000000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":518163000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":352000.0,"AssetsCurrent_0_Q2_USD":654666000.0,"Assets_0_Q2_USD":679540000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":12555751.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":23125000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":11863000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":11863000.0,"AdditionalPaidInCapital_0_Q2_USD":763755000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q2_USD":-17285000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":625000.0,"AccountsReceivableNetCurrent_0_Q2_USD":14402000.0,"DeferredRevenueNoncurrent_0_Q2_USD":426021000.0,"DueToRelatedPartiesCurrent_0_Q2_USD":334000.0,"DueToRelatedPartiesNoncurrent_0_Q2_USD":358700000.0,"EarningsPerShareBasic_1_Q2_USD":-0.23,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":3250000.0,"InterestExpense_2_Q2_USD":6999000.0,"InterestExpense_1_Q2_USD":3494000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":4414000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-1696000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":-1798000.0,"IncreaseDecreaseInOperatingLeaseLiability_2_Q2_USD":-869000.0,"IncreaseDecreaseInInventories_2_Q2_USD":3530000.0,"IncreaseDecreaseInDueToRelatedPartiesCurrent_2_Q2_USD":-209000.0,"IncreaseDecreaseInDeferredRevenue_2_Q2_USD":28652000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":1722000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":10832000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":931000.0,"IncreaseDecreaseInAccountsPayableTrade_2_Q2_USD":-9519000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-149000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-82489000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-21740000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":0.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":0.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":109600000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":17111000.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":-0.0092,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":0.0069,"EarningsPerShareDiluted_2_Q2_USD":-0.9,"EarningsPerShareDiluted_1_Q2_USD":-0.23,"EarningsPerShareBasic_2_Q2_USD":-0.9,"IncomeTaxExpenseBenefit_2_Q2_USD":762000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":92019987.0,"Ticker":"MYOV","CIK":"1679082","name":"MYOVANT SCIENCES LTD.","OfficialName":"Myovant Sciences Ltd. Common Shares","form":"10-Q","period":"20210930","fy":"2022.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1001965304.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20211026"}]